Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACCDNASDAQ:ALLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACCDAccolade$7.02$7.02$3.08▼$7.03$575.59M2.11.55 million shsN/AALLOAllogene Therapeutics$1.20+5.8%$1.30$0.86▼$3.78$261.38M0.313.25 million shs688,730 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACCDAccolade0.00%0.00%0.00%+0.43%+96.09%ALLOAllogene Therapeutics-4.24%-7.38%-3.00%-17.52%-51.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACCDAccolade0.8368 of 5 stars1.00.00.04.80.02.50.6ALLOAllogene Therapeutics3.358 of 5 stars4.51.00.00.02.23.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACCDAccolade 2.00Hold$6.57-6.41% DownsideALLOAllogene Therapeutics 2.90Moderate Buy$8.44606.65% UpsideCurrent Analyst Ratings BreakdownLatest ACCD and ALLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ALLOAllogene TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.005/14/2025ALLOAllogene TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.005/14/2025ALLOAllogene TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$12.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACCDAccolade$446.72M1.29N/AN/A$5.75 per share1.22ALLOAllogene Therapeutics$20K13,069.12N/AN/A$2.01 per share0.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACCDAccolade-$99.81M-$2.25N/AN/AN/A-40.36%-20.74%-11.33%N/AALLOAllogene Therapeutics-$257.59M-$1.23N/AN/AN/AN/A-52.98%-41.28%8/6/2025 (Estimated)Latest ACCD and ALLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALLOAllogene Therapeutics-$0.28-$0.28N/A-$0.28$0.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACCDAccoladeN/AN/AN/AN/AN/AALLOAllogene TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACCDAccolade0.672.632.63ALLOAllogene TherapeuticsN/A9.719.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACCDAccolade84.99%ALLOAllogene Therapeutics83.63%Insider OwnershipCompanyInsider OwnershipACCDAccolade8.20%ALLOAllogene Therapeutics13.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACCDAccolade2,35081.99 million74.90 millionOptionableALLOAllogene Therapeutics310218.73 million189.86 millionOptionableACCD and ALLO HeadlinesRecent News About These CompaniesALLO - Allogene Therapeutics Inc Dividends - MorningstarJune 27, 2025 | morningstar.comMAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 22, 2025 | marketbeat.comSystemic Lupus Erythematosus Pipeline Heats Up as 120+ Companies Advance Cutting-Edge Therapies | DelveInsightJune 18, 2025 | theglobeandmail.comWhy Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?June 12, 2025 | zacks.comZacks Research Issues Optimistic Forecast for ALLO EarningsJune 6, 2025 | marketbeat.comAll You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to BuyJune 4, 2025 | zacks.comHC Wainwright Issues Optimistic Forecast for ALLO EarningsJune 4, 2025 | marketbeat.comQ1 Earnings Forecast for ALLO Issued By HC WainwrightJune 3, 2025 | marketbeat.comAllogene Therapeutics Presents Promising Phase 1 Data for ALLO-316 in Renal Cell CarcinomaJune 2, 2025 | msn.comBank of America Corp DE Buys 579,818 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)June 2, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Sold by Jane Street Group LLCJune 2, 2025 | marketbeat.comAllogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCOJune 1, 2025 | globenewswire.comAllogene Therapeutics: Buying Around A Potential ASCO Lazarus MomentMay 29, 2025 | seekingalpha.comAllogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)May 28, 2025 | seekingalpha.comAllogene shares update on CAR T-cell therapies at ASCO meetingMay 24, 2025 | investing.comAllogene Therapeutics Announces Participation in Upcoming Investor ConferencesMay 23, 2025 | globenewswire.comAllogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-CelMay 22, 2025 | globenewswire.comUndervalued Opportunities: 3 Penny Stocks With Market Caps Above $30MMay 22, 2025 | finance.yahoo.comRegeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staffMay 17, 2025 | biopharmadive.comBAllogene Therapeutics falls after trial delay, rating downgrade post Q1 resultsMay 15, 2025 | msn.comAllogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 15, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACCD and ALLO Company DescriptionsAccolade NASDAQ:ACCD$7.02 0.00 (0.00%) As of 04/8/2025Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington.Allogene Therapeutics NASDAQ:ALLO$1.20 +0.07 (+5.75%) As of 12:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
